← All trials
NCT04829383
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 22, 2021
- Primary completion
- May 31, 2022
- Completion date
- Jul 31, 2024
- First posted
- Apr 2, 2021
- Last posted
- Oct 27, 2021
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rutgers UniversityLead sponsor
- Rutgers UniversityOverall official - principal investigator
- Rutgers UniversityCollaborator
- GenentechCollaborator
- Big Ten Cancer Research ConsortiumSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.